Friday, 22 November 2019 | 12:45-14:15

From Clinical Trials to Practice:

Changing the Trajectory for Metastatic Breast Cancer Patients



Room 324, Level 3 **Suntec Convention & Exhibition Centre** Singapore

Join a panel of international and regional thought-leaders as they discuss key advances in the field of HR+ HER2mBC, with a focus on CDK4/6 inhibitors, and how these new tools help us better navigate the HR+ HER2- mBC treatment journey in today's world.

PROGRAM

TIME	TOPIC & FACULTY
12:45	Welcome and introduction Dr Yen-Shen Lu (Taiwan) and Dr Yoon Sim Yap (Singapore)
12:50	From clinical trials to practice: Changing the trajectory for metastatic breast cancer (mBC) patients Dr Richard Finn (USA)
13:30	Palbociclib: Real-world outcomes Dr Senthil Rajappa (India)
13:45	Panel discussion: Management of mBC in Asian patients Moderator Dr Senthil Rajappa (India) Panelists Dr Richard Finn (USA), Dr William Foo (Hong Kong), Dr Suthinee Ithimakin (Thailand), Dr Joline Lim (Singapore), Dr Mastura Md Yusof (Malaysia)
14:05	Q&A
14:15	Session close

Complimentary lunch will be provided to symposium attendees.

FACULTY

Co-chairpersons:



Dr Yen-Shen Lu National Taiwan University College of Medicine Taipei, Taiwan



Dr Yoon Sim Yap Senior Consultant National Cancer Centre Singapore

Speakers:



Dr Richard Finn UCLA David Geffen School of Medicine Los Angeles, USA



Dr Senthil Rajappa Basavatarakam Indo-American Cancer Hospital and Research Hyderabad, India

Panelists:



Dr William Foo Hong Kong Baptist Hong Kong



Dr Suthinee Ithimakin Mahidol University Bangkok, Thailand



Dr Joline Lim National University Cancer Institute Singapore



Dr Mastura Md Yusof Pantai Hospital Kuala Lumpur Kuala Lumpur, Malaysia



Pfizer Private Limited

80 Pasir Panjang Road, #16-81/82, Mapletree Business City, Singapore 117372